5. Robert Parkinson - Baxter International

2014 pay: $15.3 million
2015 pay: $17.8 million

Robert Parkinson had a lot on his plate during his last year as Baxter’s ($BAX) CEO in 2015. The med tech helmsman oversaw a spinout of the company’s biopharma business, Baxalta, before former Covidien CEO Jose Almeida took the reins in 2016.

In January 2015, Parkinson said that it would be a “challenging year” for Baxter. But the company is “excited about our future prospects and we’re poised for improved performance in 2016 and beyond,” he said at the time.

After the Baxalta spinout, Baxter wanted to focus on the dialyzer business it bought from Gambro in September 2013 for $4 billion. The company has already said that it would invest $600 million to expand production capacity to meet dialyzer demand.

In October 2015, Baxter revealed that Parkinson would retire as CEO and that Jose Almeida would step in as the company’s new CEO.  “What Joe brings to Baxter in skill and experience is imperative to the company’s stated goal of accelerating profitable growth over the near and long term,” Parkinson said at the time.

During his final year at Baxter, Parkinson took home $17.8 million in pay, including a $1.5 million base salary, $6.5 million in stock awards, $4.8 million in options and $3.6 million in non-equity incentives.

- here’s Baxter International’s proxy statement

For more:
Baxter edges closer to mid-2015 split into separate biopharma, medical product companies
At Baxter, Covidien's Almeida looks to cut costs, fuel innovation and do smaller acquisitions
Baxter makes nice with activist investor Third Point, offers board seats

5. Robert Parkinson - Baxter International

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.